Global Ganja Report

Canada's postal unions are contemplating a nationwide walk-out—exactly as legal mail-order cannabis deliveries are set to begin. Talks are ongoing, but if the strike is not averted, cannabis consumers could be left high and dry—especially in those provinces that are relying mostly or entirely on home deliveries.

A major player in Canada's legal cannabis sector is seeking to acquire a troubled US-based company—the latest example of the trend toward consolidation in the industry now crossing international borders.

Malaysia's surprise announcement that it will abolish the death penalty is a breakthrough for conservative Southeast Asia—and follows a global outcry over the death sentence meted out to a provider of medicinal cannabis oil. But will the reform come in time to save the life of Muhammad Lukman?

As legal cannabis finally becomes a reality in Canada, a policy patchwork across the country's provinces and ongoing political tussles have left many confused as to what the new system will actually look like. We break down some of the frequently asked questions. 

A growing number among Canada's First Nations are looking to legal cannabis as a path to economic empowerment. Others are deeply skeptical, recalling the bitter history of substance abuse among Canada's indigenous communities. Yet all seem united in demanding sovereign control on the cannabis question within their own reserves.

A legal medical marijuana export industry is coming to Jamaica, which has just dispatched its first shipment of cannabis oil to Canada. Long famous for its contraband product, the island nation now has a Cannabis Licensing Authority to oversee legal cultivation.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.